Role of Antibodies in Developing Drugs That Target G‐Protein‐Coupled Receptor Dimers
Authors:
- 15 July 2010
- journal article
- review article
- Published by Wiley in Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine
- Vol. 77 (4) , 374-380
Abstract
G‐protein‐coupled receptors are important molecular targets in drug discovery. These receptors play a pivotal role in physiological signaling pathways and are targeted by nearly 50% of currently available drugs. Mounting evidence suggests that G‐protein‐coupled receptors form dimers, and various studies have shown that dimerization is necessary for receptor maturation, signaling, and trafficking. However, the physiological implications of dimerization in vivo have not been well explored because detection of GPCR dimers in endogenous systems has been a challenging task. One exciting new approach to this challenge is the generation of antibodies against specific G‐protein‐coupled receptor dimers. Such antibodies could be used as tools for characterization of heteromer‐specific function; as reagents for their purification, tissue localization, and regulation in vivo; and as probes for mapping their functional domains. In addition, such antibodies could serve as alternative ligands for G‐protein‐coupled receptor heteromers. Thus, heteromer‐specific antibodies represent novel tools for the exploration and manipulation of G‐protein‐coupled receptor‐dimer pharmacology. Mt Sinai J Med 77:374–380, 2010. © 2010 Mount Sinai School of MedicineKeywords
This publication has 65 references indexed in Scilit:
- Allosteric Modulators of G Protein-Coupled Receptors: Future Therapeutics for Complex Physiological DisordersThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Post-activation-mediated Changes in Opioid Receptors Detected by N-terminal AntibodiesJournal of Biological Chemistry, 2008
- Identification of a serotonin/glutamate receptor complex implicated in psychosisNature, 2008
- Hemopressin is an inverse agonist of CB 1 cannabinoid receptorsProceedings of the National Academy of Sciences of the United States of America, 2007
- Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of μ‐ and δ‐opioid receptor antagonistsBritish Journal of Pharmacology, 2007
- μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesisBritish Journal of Pharmacology, 2006
- Airway smooth muscle prostaglandin-EP1 receptors directly modulate 2-adrenergic receptors within a unique heterodimeric complexJournal of Clinical Investigation, 2006
- Targeting opioid receptor heterodimers: Strategies for screening and drug developmentThe AAPS Journal, 2006
- Dual Inhibition of β-Adrenergic and Angiotensin II Receptors by a Single AntagonistCirculation, 2003